Please login to the form below
subcutaneous injection
This page shows the latest subcutaneous injection news and features for those working in and with pharma, biotech and healthcare.
Janssen’s Stelara approved by FDA for psoriatic arthritis in paediatric patients
The treatment is administered as a subcutaneous injection four times per year after two starter doses for the treatment of paediatric patients aged six years and older with active PsA.
Latest news
-
Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
Roche has announced results from its phase 3 IMscin001 study assessing Tecentriq (atezolizumab) as a subcutaneous formulation. ... The investigational subcutaneous formulation combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery
-
AstraZeneca’s Saphnelo to be approved in Europe for lupus
Saphnelo is available as an infusion but AstraZeneca is running a phase 3 trial to assess the antibody as a subcutaneous injection.
-
New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU
New administration offers same efficacy as subcutaneous injection. The European Commission (EC) has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy for the treatment of ... In 2014, Plegridy was initially
-
Pfizer doses first patient in investigational haemophilia drug trial
Based on the phase 2 study findings to date, marstacimab may have the potential to offer improved bleed control via subcutaneous injection and potentially eliminate the need for prophylactic factor replacement,
-
Novartis scores CHMP backing for cholesterol drug Leqvio
In these trials, Leqvio demonstrated LDL-C reduction of up to 52% with two doses per year administered as a subcutaneous injection, following an initial dose and one at three months,
More from news
Approximately 1 fully matching, plus 97 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
It’s given as a subcutaneous injection that takes less than a minute to deliver every two weeks, around 75% fewer injections than other products for HAE prevention. ... Injection volumes are lower, it can be taken weekly as well as monthly and can be
-
Implementing eHealth innovation
Growth hormone treatment (GHT) is only available on prescription and is given as a subcutaneous injection (directly under the skin). ... complete, partial, missed) of each injection, and uploads this data wirelessly from the patients’ homes to the
-
Deal Watch November 2016
Arsia has a proprietary viscosity reducing technology and know-how to enable the development of high concentration formulations of biologics that can be administered by subcutaneous injection rather than intravenously. ... Invossa, cell-mediated gene
-
Deal Watch July 2016
cells. The product has been submitted to the EMA following a phase III trial showing safety and efficacy of a single injection in the treatment of complex peri-anal fistulas, and ... The presentation is subcutaneous injection in both indications, leaving
-
Oral biologics delivery still elusive
At the moment, biologics are generally delivered by intravenous or subcutaneous injection, which is effective but not desirable for patients, particularly for chronic conditions.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
AP Pharma overhauls senior management team
drug delivery platform, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
The Difference Collective
Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
